Target Price | $124.11 |
Price | $72.89 |
Potential | 70.27% |
Number of Estimates | 18 |
18 Analysts have issued a price target Moderna 2025 . The average Moderna target price is $124.11. This is 70.27% higher than the current stock price. The highest price target is $310.00 325.30% , the lowest is $58.00 20.43% . | |
A rating was issued by 26 analysts: 10 Analysts recommend Moderna to buy, 14 to hold and 2 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Moderna stock has an average upside potential 2025 of 70.27% . Most analysts recommend the Moderna stock at Hold. |
20 Analysts have issued a sales forecast Moderna 2024 . The average Moderna sales estimate is $3.3b . This is 33.70% lower than the revenue of the last 12 months(TTM). The highest sales forecast is $4.5b 11.21% , the lowest is $2.8b 43.65% .
This results in the following potential growth metrics:
2023 | $6.8b | 64.21% |
---|---|---|
2024 | $3.3b | 51.12% |
2025 | $3.9b | 15.68% |
2026 | $5.6b | 45.10% |
2027 | $8.1b | 45.06% |
2028 | $13.0b | 59.76% |
9 Analysts have issued an Moderna EBITDA forecast 2024. The average Moderna EBITDA estimate is $-3.6b . This is 13.52% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $-2.7b 33.32% , the lowest is $-4.0b 3.88% .
This results in the following potential growth metrics and future EBITDA Margins:
2023 | $-3.6b | 137.72% |
---|---|---|
2024 | $-3.6b | 1.86% |
2025 | $-2.8b | 21.73% |
2026 | $-2.0b | 29.13% |
2027 | $-25.0m | 98.74% |
2023 | -53.01% | 205.37% |
---|---|---|
2024 | -106.45% | 100.80% |
2025 | -72.03% | 32.33% |
2026 | -35.18% | 51.16% |
2027 | -0.31% | 99.12% |
13 Moderna Analysts have issued a net profit forecast 2024. The average Moderna net profit estimate is $-3.6b . This is 39.80% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $-2.8b 52.86% , the lowest is $-3.9b 34.01% .
This results in the following potential growth metrics and future Net Margins:
2023 | $-4.7b | 161.39% |
---|---|---|
2024 | $-3.6b | 24.97% |
2025 | $-3.0b | 15.48% |
2026 | $-2.1b | 31.02% |
2027 | $-1.1b | 44.63% |
2028 | $-1.2b | 8.24% |
2023 | -69.28% | 271.51% |
---|---|---|
2024 | -106.35% | 53.51% |
2025 | -77.70% | 26.94% |
2026 | -36.94% | 52.46% |
2027 | -14.10% | 61.83% |
2028 | -9.55% | 32.27% |
13 Analysts have issued a Moderna forecast for earnings per share. The average Moderna <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is $-9.26 . This is 39.79% higher than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is $-7.25 52.86% , the lowest is $-10.15 34.01% .
This results in the following potential growth metrics and future valuations:
2023 | $-12.34 | 161.39% |
---|---|---|
2024 | $-9.26 | 24.96% |
2025 | $-7.83 | 15.44% |
2026 | $-5.40 | 31.03% |
2027 | $-2.99 | 44.63% |
2028 | $-3.24 | 8.36% |
Current | -4.74 | 117.94% |
---|---|---|
2024 | -7.87 | 66.03% |
2025 | -9.31 | 18.30% |
2026 | -13.50 | 45.01% |
2027 | -24.39 | 80.67% |
2028 | -22.53 | 7.63% |
Based on analysts' sales estimates for 2024, the Moderna stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of 6.22 and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of 8.38 .
This results in the following potential growth metrics and future valuations:
Current | 4.13 | 22.55% |
---|---|---|
2024 | 6.22 | 50.65% |
2025 | 5.38 | 13.56% |
2026 | 3.71 | 31.08% |
2027 | 2.56 | 31.07% |
2028 | 1.60 | 37.41% |
Current | 5.56 | 36.88% |
---|---|---|
2024 | 8.38 | 50.82% |
2025 | 7.24 | 13.56% |
2026 | 4.99 | 31.08% |
2027 | 3.44 | 31.07% |
2028 | 2.15 | 37.40% |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.